A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity
Hoffmann-La Roche
Summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * HbA1c ≥ 48 mmol/mol (6.5%), measured by the central laboratory at screening * Known history of Type 1 or Type 2 diabetes mellitus * Current or previous treatment with petrelintide or any other amylin analog
Interventions
- Combination ProductPetrelintide
Petrelintide will be administered subcutaneously (SC) using a drug-device combination product.
- Combination ProductPlacebo
Petrelintide-matching placebo will be administered SC using a drug-device combination product.
Locations (8)
- Pinnacle Research GroupAnniston, Alabama
- CMR of Greater New Haven, LLCHamden, Connecticut
- Suncoast Clinical ResearchNew Port Richey, Florida
- Progressive Medical ResearchPort Orange, Florida
- Solaris Clinical Research (SCR)Meridian, Idaho
- Rochester Clinical Research, IncRochester, New York